stockrow
Friday 6 November 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
30.53
2.14
+7.54%
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Shares outstanding
Immunovant, Inc.'s shares outstanding at the end of fiscal 2026 was $182.4M, up 20.4% from $151.6M in fiscal 2025. At the end of the quarter to 30 June 2026 it was $205.5M. Over the past ten years it has ranged from $14.4M (fiscal 2018) to $182.4M (fiscal 2026) — the current reading is the highest in ten years. Immunovant, Inc. ranks 44th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $182.4M | 20.35% |
| FY2025 | $151.6M | 9.76% |
| FY2024 | $138.1M | 12.21% |
| FY2023 | $123.1M | 12.21% |
| FY2022 | $109.7M | 24.98% |
| FY2021 | $87.8M | 103.15% |
| FY2020 | $43.2M | 94.84% |
| FY2019 | $22.2M | 54.23% |
| FY2018 | $14.4M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $205.5M | 12.68% |
| Mar 2026 | $182.4M | 0.50% |
| Dec 2025 | $181.5M | 4.53% |
| Sep 2025 | $173.6M | 1.62% |
| 27 more quarters | Free account |
Against its own ten years
Low $14.4M
High $182.4M
Ten-year median
$109.7M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. | $205.5M |
| IONS Ionis Pharmaceuticals, Inc. compare | $165.4M |
| CGON CG Oncology, Inc. compare | $88.2M |
| PTCT PTC Therapeutics, Inc. compare | $83.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $66.1M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| MANE Veradermics Incorporated compare | $40.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
| LGND Ligand Pharmaceuticals Incorporated compare | $20.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item